138 related articles for article (PubMed ID: 38777176)
21. Pediatric drug formulations: a review of challenges and progress.
Ivanovska V; Rademaker CM; van Dijk L; Mantel-Teeuwisse AK
Pediatrics; 2014 Aug; 134(2):361-72. PubMed ID: 25022739
[TBL] [Abstract][Full Text] [Related]
22. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
23. Influence of poloxamers on the dissolution performance and stability of controlled-release formulations containing Precirol ATO 5.
Jannin V; Pochard E; Chambin O
Int J Pharm; 2006 Feb; 309(1-2):6-15. PubMed ID: 16376034
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of distributional homogeneity of pharmaceutical formulation using laser direct infrared imaging.
Sacré PY; Alaoui Mansouri M; De Bleye C; Coïc L; Hubert P; Ziemons E
Int J Pharm; 2022 Jan; 612():121373. PubMed ID: 34906650
[TBL] [Abstract][Full Text] [Related]
25. Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies.
Gaspar DP; Faria V; Gonçalves LM; Taboada P; Remuñán-López C; Almeida AJ
Int J Pharm; 2016 Jan; 497(1-2):199-209. PubMed ID: 26656946
[TBL] [Abstract][Full Text] [Related]
26. Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization.
Rashid MA; Muneer S; Wang T; Alhamhoom Y; Rintoul L; Izake EL; Islam N
PLoS One; 2021; 16(4):e0249683. PubMed ID: 33848310
[TBL] [Abstract][Full Text] [Related]
27. The impact of drying method and formulation on the physical properties and stability of methionyl human growth hormone in the amorphous solid state.
Abdul-Fattah AM; Lechuga-Ballesteros D; Kalonia DS; Pikal MJ
J Pharm Sci; 2008 Jan; 97(1):163-84. PubMed ID: 17722086
[TBL] [Abstract][Full Text] [Related]
28. Design and development of oral mucoadhesive multiparticulate system containing atenolol: in vitro-in vivo characterization.
Belgamwar VS; Surana SJ
Chem Pharm Bull (Tokyo); 2010 Sep; 58(9):1168-75. PubMed ID: 20823595
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of miscibility and polymorphism of synthetic and natural lipids for nanostructured lipid carrier (NLC) formulations by Raman mapping and multivariate curve resolution (MCR).
Mitsutake H; Ribeiro LNM; Rodrigues da Silva GH; Castro SR; de Paula E; Poppi RJ; Breitkreitz MC
Eur J Pharm Sci; 2019 Jul; 135():51-59. PubMed ID: 31071439
[TBL] [Abstract][Full Text] [Related]
30. Amended final report on the safety assessment of glyceryl dilaurate, glyceryl diarachidate, glyceryl dibehenate, glyceryl dierucate, glyceryl dihydroxystearate, glyceryl diisopalmitate, glyceryl diisostearate, glyceryl dilinoleate, glyceryl dimyristate, glyceryl dioleate, glyceryl diricinoleate, glyceryl dipalmitate, glyceryl dipalmitoleate, glyceryl distearate, glyceryl palmitate lactate, glyceryl stearate citrate, glyceryl stearate lactate, and glyceryl stearate succinate.
Int J Toxicol; 2007; 26 Suppl 3():1-30. PubMed ID: 18273450
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis-B surface antigen (HBsAg) powder formulation: process and stability assessment.
Maa YF; Ameri M; Shu C; Zuleger CL; Che J; Osorio JE; Payne LG; Chen D
Curr Drug Deliv; 2007 Jan; 4(1):57-67. PubMed ID: 17269918
[TBL] [Abstract][Full Text] [Related]
32. Formulation of multiparticulate systems as lyophilised orally disintegrating tablets.
Alhusban F; Perrie Y; Mohammed AR
Eur J Pharm Biopharm; 2011 Nov; 79(3):627-34. PubMed ID: 21693189
[TBL] [Abstract][Full Text] [Related]
33. Characterization of Complex Drug Formulations Using Cryogenic Scanning Electron Microscopy (Cryo-SEM).
Liang J; Koo B; Wu Y; Manna S; Noble JM; Patel M; Park JH; Kozak D; Wang Y; Zheng J
Curr Protoc; 2022 Apr; 2(4):e406. PubMed ID: 35384403
[TBL] [Abstract][Full Text] [Related]
34. Impact of formulation and process variables on solid-state stability of theophylline in controlled release formulations.
Korang-Yeboah M; Rahman Z; Shah D; Mohammad A; Wu S; Siddiqui A; Khan MA
Int J Pharm; 2016 Feb; 499(1-2):20-28. PubMed ID: 26688036
[TBL] [Abstract][Full Text] [Related]
35. Quantifying Disproportionation in Pharmaceutical Formulations with
Hirsh DA; Su Y; Nie H; Xu W; Stueber D; Variankaval N; Schurko RW
Mol Pharm; 2018 Sep; 15(9):4038-4048. PubMed ID: 30016112
[TBL] [Abstract][Full Text] [Related]
36. Planning Implications Related to Sterilization-Sensitive Science Investigations Associated with Mars Sample Return (MSR).
Velbel MA; Cockell CS; Glavin DP; Marty B; Regberg AB; Smith AL; Tosca NJ; Wadhwa M; Kminek G; Meyer MA; Beaty DW; Carrier BL; Haltigin T; Hays LE; Agee CB; Busemann H; Cavalazzi B; Debaille V; Grady MM; Hauber E; Hutzler A; McCubbin FM; Pratt LM; Smith CL; Summons RE; Swindle TD; Tait KT; Udry A; Usui T; Westall F; Zorzano MP
Astrobiology; 2022 Jun; 22(S1):S112-S164. PubMed ID: 34904892
[TBL] [Abstract][Full Text] [Related]
37. Applications of cathodoluminescence spectroscopy and imaging in the characterisation of pharmaceutical materials.
Nichols G
Eur J Pharm Sci; 2012 Jan; 45(1-2):19-42. PubMed ID: 22074938
[TBL] [Abstract][Full Text] [Related]
38. Acceptability of placebo multiparticulate formulations in children and adults.
Lopez FL; Mistry P; Batchelor HK; Bennett J; Coupe A; Ernest TB; Orlu M; Tuleu C
Sci Rep; 2018 Jun; 8(1):9210. PubMed ID: 29907752
[TBL] [Abstract][Full Text] [Related]
39. Characterization of pharmaceutically relevant materials at the solid state employing chemometrics methods.
Calvo NL; Maggio RM; Kaufman TS
J Pharm Biomed Anal; 2018 Jan; 147():538-564. PubMed ID: 28666554
[TBL] [Abstract][Full Text] [Related]
40. Application of Vibrational Spectroscopy to Study Solid-state Transformations of Pharmaceuticals.
Erxleben A
Curr Pharm Des; 2016; 22(32):4883-4911. PubMed ID: 27464723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
